Modular Medical Inc (MODD) Peer Comparison

$3.61

$0.30 (9.06%)

As on 27-Aug-2026 16:29EDT

Market cap

$29 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

2.6

Div. Yield

0 %

Edit

	Modular Medical Inc (MODD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	29	12,753	10,906	9,762	10,222
Revenue ($ Mln)	--	1,505	613	2,589	785
Net Profit ($ Mln)	-28.03	160.59	-188.05	222.40	41.54
Net Margin (%)	--	10.67	-30.68	8.59	5.29
RoE (%)	-336.75	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.35	--	44.47	251.57
Price-To-Book	2.63	8.41	16.38	1.26	4.84

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Modular Medical Inc (MODD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	0.00	1,403.67	507.44	2,583.20	738.26
Cost of Revenue	1.67	461.23	114.23	1,239.60	390.63
Gross Profit	-1.67	942.44	393.22	1,343.60	347.62
Operating Expenses	25.89	753.19	479.95	1,077.50	288.05
Operating Profit (EBIT)	-27.56	189.25	-86.73	270.50	59.58
Other Income	--	--	--	--	--
Profit before Tax	-28.24	205.13	-193.04	995.50	62.38
Provision for Tax	0.00	27.44	-5.35	235.60	13.49
Profit after Tax (Net Income)	-28.24	177.69	-187.69	759.90	48.89
Minority Interest	--	--	--	--	--
Consolidated Profit	--	177.69	--	--	--

Liabilities ($ Mln)

	Modular Medical Inc (MODD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	12.96	1,427.60	656.16	7,453.60	2,106.13
Minority Interest	--	--	--	--	--
Non-Current Liabilities	0.00	215.78	136.06	2,605.90	707.74
Current Liabilities	1.87	183.13	101.28	517.00	135.83
Total Liabilities	14.83	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Modular Medical Inc (MODD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	7.29	609.84	418.50	7,670.30	1,812.31
Current Assets	7.54	1,216.68	474.98	2,906.20	1,137.39
Total Assets	14.83	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	0.39	219.70	139.64	1,531.00	689.95
Net Current Assets	5.67	1,033.55	373.71	2,389.20	1,001.56

Cashflow ($ Mln)

	Modular Medical Inc (MODD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-23.75	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-3.93	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	21.53	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Modular Medical Inc (MODD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-180.78	11.76	-22.53	8.98	1.79
ROE (%)	-188.05	13.78	-26.38	10.84	2.40
ROA (%)	-168.27	10.58	-20.09	7.62	1.69
EBIT Margin (%)	--	--	--	--	--
Net Margin (%)	--	12.66	-36.99	29.42	6.62
Cash Profit Margin (%)	--	--	--	--	--

Growth Ratios

	Modular Medical Inc (MODD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	--	0.17	0.32	0.01	0.16
EBIT Growth (%)	--	--	--	--	--
Net Profit Growth (%)	-50.03	1,168.11	-28.23	141.20	291.64
EPS Growth (%)	0.54	11.64	-0.24	1.43	2.90
Book Value Growth (%)	--	--	--	--	--

Valuation Ratios

	Modular Medical Inc (MODD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-0.87	68.93	-34.59	--	189.42
Price / Book Value	1.90	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-0.70	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Modular Medical Inc (MODD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.03	0.15	0.21	0.21	0.33
Short term debt to equity ratio	0.03	0.01	--	0.01	0.01
Current Ratio	4.03	6.64	4.69	5.62	8.37
Quick Ratio	--	4.29	4.06	4.19	7.12
Interest Coverage	--	157.46	-40.65	21.32	3.69

Operating Efficiency Ratios

	Modular Medical Inc (MODD)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	--	13.54	21.40	18.29	21.48
Asset Turnover	0.00	0.84	0.54	0.26	0.26
Receivable days	--	46.54	60.95	65.39	72.41
Inventory Days	--	331.92	193.84	221.09	146.53
Payable days	145.27	26.16	60.19	37.02	29.05
Cash Conversion Cycle	--	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly